Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RR/MDR TB in Croatia

ABSTRACT: RR/MDR TB in Croatia

PROVIDER: PRJEB86988 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR14722664_1.fastq.gz	Fastqsanger.gz
	ERR14722664_2.fastq.gz	Fastqsanger.gz
	ERR14722665_1.fastq.gz	Fastqsanger.gz
	ERR14722665_2.fastq.gz	Fastqsanger.gz
	ERR14722666_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Rwanda RR-TB

Project description:A longitudinal nationwide collection of RR-TB

| PRJEB43270 | ENA

Serum protein abundance of MDR-TB patients based on PRM analysis

Project description:A mass spectrometry strategy of parallel reaction monitoring was used to detect and validate differential proteins in serum. Here are the data including 3 groups of MDR-TB, DS-TB and HC.

2020-09-25 | PXD019604 | Pride

MDR strains

Project description:MDR strains Croatia

| PRJEB75504 | ENA

Blood serum protein abundance of MDR-TB patients based on data-independent acquisition

Project description:A mass spectrometry strategy of data-independent acquisition was used to detect differential proteins in serum. Here are the data including 3 groups of MDR-TB, DS-TB and HC.

2020-09-24 | PXD019856 |

Macrophage responses to MDR M.tuberculosis infection

Project description:The emergence of multidrug resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, resistant to the frontline anti-tubercular drugs rifampicin and isoniazid, forces treatment with less effective and toxic second-line drugs and stands to derail TB control efforts. However, the immune response to MDR Mtb infection remains poorly understood. Here, we determined the RNA transcriptional profile of in vitro generated macrophages to infection with either drug susceptible Mtb HN878 or MDR Mtb W_7642 infection.

2018-12-26 | GSE115495 | GEO

Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB

Project description:Cross-transmission of MDR-TB in Kuwait

| PRJEB32943 | ENA

TB Argentina

Project description:Recurrences of MDR-TB in Argentina

| PRJEB41837 | ENA

Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort.

Project description:Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- and middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR) and rifampicin resistant (RR) TB populations show high HCV prevalence. Current WHO guidelines do not routinely advise HCV testing during MDR-TB treatment, despite HCV being a risk factor for drug-induced liver complications in TB patients. This study investigates the co-treatment of MDR/RR-TB and HCV, using data from the TB-PRACTECAL trial. Data were collected as part of the TB-PRACTECAL clinical trial. All participants were screened for HCV at baseline. Participants who were HCV antibody positive and those who were treated for hepatitis C with Direct Acting Antivirals (DAAs) were extracted and compared to overall cohort characteristics. The characteristics of participants concomitantly treated with direct-acting antivirals are described including hepatitis treatment outcomes and adverse events. Among 552 participants from Belarus, Uzbekistan, and South Africa, 24 (4.3%) were HCV antibody positive. Unfavourable TB treatment outcomes were noted in 106/523 (22%) of the HCV-negative, 8/18 (44%) of the HCV-seropositive, and 2/7 (29%) of HCV-confirmed participants treated with DAAs. Of the six participants who received concurrent HCV and MDR/RR TB treatment, three were cured of HCV and three had no post-treatment HCV RNA test, five completed TB treatment and one discontinued treatment due to a severe adverse reaction. Concurrent treatment of MDR-TB and HCV, including in HIV patients, showed promising outcomes with no significant adverse events. The findings support the potential benefits of integrating HCV care into MDR-TB management.

| S-EPMC11421810 | biostudies-literature

Project description:Drosophila melanogaster Tb, Tubby, is differentially expressed in 9 experiment(s);

| FBgn0243586 | ExpressionAtlas

Project description:Drosophila melanogaster Tb, Tubby, is expressed in 2 baseline experiment(s);

| FBgn0243586 | ExpressionAtlas